India Proposes Pharma Supply Chain and Regulatory Reforms
Key Points
- Draft notification targets medicinal gases, gelatin capsules, and disinfectants for regulatory flexibility.
- Stakeholders raised concerns about revised Schedule M applicability to specific manufacturing processes.
- Public consultation period opens for objections and suggestions on the proposed regulatory changes.
Editorial Deep Dive & Context
The Union Ministry of Health and Family Welfare has proposed amendments to the Drugs Rules, 1945, through draft Gazette Notification G.S.R. 985 (E) dated November 6. The initiative introduces two critical components: the mandatory incorporation of Good Storage and Distribution Practices (GSDP) guidelines and targeted regulatory flexibility under the revised Schedule M framework.
The GSDP framework, built upon Central Drugs Standard Control Organisation (CDSCO) guidance, mandates strict protocols for procurement, storage, transportation, and documentation. This aims to mitigate supply chain risks such as contamination, falsification, and unauthorized distribution, ensuring product integrity reaches patients.
Concurrently, the ministry addresses stakeholder concerns regarding medicinal gases, empty gelatin capsules, and disinfectant fluids. Following deliberations by the Drugs Technical Advisory Board on February 16, 2026, the proposal recommends continuing exemptions for these categories where revised manufacturing requirements were deemed irrelevant. These measures aim to align regulatory oversight with actual manufacturing processes without diluting safety standards. Licensing authorities will gain discretion to make product-specific decisions based on scientific considerations.
Live Updates & Related Coverage (1)
Chronological updates and connected stories across this news arc. Tap any item to explore.
India Proposes Pharma Supply Chain and Regulatory Reforms
The Ministry invites public comments on draft notifications proposing GSDP integration and Schedule M exemptions for select drug categories